Perfromance Wealth Partners LLC Sells 705 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Perfromance Wealth Partners LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 19.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,921 shares of the company's stock after selling 705 shares during the quarter. Perfromance Wealth Partners LLC's holdings in IDEXX Laboratories were worth $1,227,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in IDXX. United Capital Financial Advisors LLC raised its position in shares of IDEXX Laboratories by 0.9% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after buying an additional 22 shares in the last quarter. Gabelli Funds LLC grew its position in IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after acquiring an additional 25 shares in the last quarter. Bigelow Investment Advisors LLC increased its stake in IDEXX Laboratories by 1.9% during the first quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock worth $596,000 after acquiring an additional 27 shares during the last quarter. Forum Financial Management LP raised its position in IDEXX Laboratories by 4.9% during the fourth quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after purchasing an additional 29 shares during the period. Finally, Grimes & Company Inc. lifted its stake in shares of IDEXX Laboratories by 0.6% in the 1st quarter. Grimes & Company Inc. now owns 4,502 shares of the company's stock valued at $1,890,000 after purchasing an additional 29 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent research reports. Stifel Nicolaus increased their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Leerink Partners raised their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Finally, Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $546.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $523.92 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. The stock's fifty day moving average is $486.81 and its two-hundred day moving average is $447.64. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $530.73. The company has a market capitalization of $42.13 billion, a PE ratio of 48.42, a price-to-earnings-growth ratio of 3.80 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.71 earnings per share. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.